Alexander Stephan Noguerola

Array ( [id] => 11336730 [patent_doc_number] => 20160362485 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-15 [patent_title] => 'SELF-BUFFERING PROTEIN FORMULATIONS' [patent_app_type] => utility [patent_app_number] => 15/230039 [patent_app_country] => US [patent_app_date] => 2016-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 31282 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15230039 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11289170 [patent_doc_number] => 20160339102 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-24 [patent_title] => 'SELF-BUFFERING PROTEIN FORMULATIONS' [patent_app_type] => utility [patent_app_number] => 15/228955 [patent_app_country] => US [patent_app_date] => 2016-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 31304 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15228955 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11336729 [patent_doc_number] => 20160362484 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-15 [patent_title] => 'SELF-BUFFERING PROTEIN FORMULATIONS' [patent_app_type] => utility [patent_app_number] => 15/227880 [patent_app_country] => US [patent_app_date] => 2016-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 31312 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15227880 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11270537 [patent_doc_number] => 20160333084 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-17 [patent_title] => 'METHODS AND COMPOSITIONS FOR MODULATION OF OLFML3 MEDIATED ANGIOGENESIS' [patent_app_type] => utility [patent_app_number] => 15/227931 [patent_app_country] => US [patent_app_date] => 2016-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 24788 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15227931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16275605 [patent_doc_number] => 10758612 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-01 [patent_title] => Antibodies to tumor associated complex N-glycans with terminal GlcNAcb residues and methods of use thereof [patent_app_type] => utility [patent_app_number] => 15/744658 [patent_app_country] => US [patent_app_date] => 2016-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 29 [patent_no_of_words] => 21979 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15744658 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11403040 [patent_doc_number] => 20170023579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-26 [patent_title] => 'MULTIPLEX HER2 AND ESTROGEN RECEPTOR CO-STAINING ASSAYS FOR DETECTING TUMOR HETEROGENEITY' [patent_app_type] => utility [patent_app_number] => 15/201273 [patent_app_country] => US [patent_app_date] => 2016-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 22520 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15201273 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16058509 [patent_doc_number] => 10688178 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-23 [patent_title] => AntiPlexin A1 agonist antibody [patent_app_type] => utility [patent_app_number] => 15/741225 [patent_app_country] => US [patent_app_date] => 2016-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 13 [patent_no_of_words] => 18321 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 143 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15741225 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11576842 [patent_doc_number] => 09632093 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-25 [patent_title] => 'Detecting neoplasm' [patent_app_type] => utility [patent_app_number] => 15/197105 [patent_app_country] => US [patent_app_date] => 2016-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 15680 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 224 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15197105 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11514345 [patent_doc_number] => 20170081420 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-23 [patent_title] => 'HETERODIMERIC ANTIBODIES TO CD3 X CD123' [patent_app_type] => utility [patent_app_number] => 15/185958 [patent_app_country] => US [patent_app_date] => 2016-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 192 [patent_figures_cnt] => 192 [patent_no_of_words] => 26678 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15185958 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12099240 [patent_doc_number] => 09856327 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-02 [patent_title] => 'Heterodimeric antibodies to CD3 X CD123' [patent_app_type] => utility [patent_app_number] => 15/186167 [patent_app_country] => US [patent_app_date] => 2016-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 204 [patent_figures_cnt] => 212 [patent_no_of_words] => 30185 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15186167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13606951 [patent_doc_number] => 20180355024 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-13 [patent_title] => HETERO-DIMERIC MULTI-SPECIFIC ANTIBODY FORMAT [patent_app_type] => utility [patent_app_number] => 15/736747 [patent_app_country] => US [patent_app_date] => 2016-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10259 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 228 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15736747 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11604475 [patent_doc_number] => 20170121777 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-04 [patent_title] => 'Method for the Diagnosis, Prognosis and Treatment of Prostate Cancer Metastasis' [patent_app_type] => utility [patent_app_number] => 15/183419 [patent_app_country] => US [patent_app_date] => 2016-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 39016 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15183419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16518722 [patent_doc_number] => 10869924 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-22 [patent_title] => PD-L1 antagonist combination treatments [patent_app_type] => utility [patent_app_number] => 15/736615 [patent_app_country] => US [patent_app_date] => 2016-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 26789 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15736615 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14700655 [patent_doc_number] => 10378062 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-13 [patent_title] => Natural-killer/T-cell lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy [patent_app_type] => utility [patent_app_number] => 15/174578 [patent_app_country] => US [patent_app_date] => 2016-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 16 [patent_no_of_words] => 6009 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 184 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15174578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16772014 [patent_doc_number] => 10983114 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Method for the in situ formation of bifunctional immunological complexes [patent_app_type] => utility [patent_app_number] => 15/580708 [patent_app_country] => US [patent_app_date] => 2016-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 10 [patent_no_of_words] => 6307 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15580708 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16063465 [patent_doc_number] => 10690674 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-23 [patent_title] => Anti-GITR antibodies for cancer diagnostics [patent_app_type] => utility [patent_app_number] => 15/578874 [patent_app_country] => US [patent_app_date] => 2016-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 7 [patent_no_of_words] => 19499 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15578874 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11077153 [patent_doc_number] => 20160274117 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-22 [patent_title] => 'METHOD FOR BIOMARKER AND DRUG-TARGET DISCOVERY FOR PROSTATE CANCER DIAGNOSIS AND TREATMENT AS WELL AS BIOMARKER ASSAYS DETERMINED THEREWITH' [patent_app_type] => utility [patent_app_number] => 15/170876 [patent_app_country] => US [patent_app_date] => 2016-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 11985 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15170876 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12227741 [patent_doc_number] => 09914976 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-13 [patent_title] => 'Methods and compositions for prostate cancer metastasis' [patent_app_type] => utility [patent_app_number] => 15/167299 [patent_app_country] => US [patent_app_date] => 2016-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 14 [patent_no_of_words] => 16183 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15167299 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12832171 [patent_doc_number] => 20180169229 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-21 [patent_title] => COMBINATION OF A PD-1 ANTAGONIST AND CPG-C TYPE OLIGONUCLEOTIDE FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 15/577369 [patent_app_country] => US [patent_app_date] => 2016-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25415 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15577369 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12999985 [patent_doc_number] => 10023650 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-17 [patent_title] => Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers [patent_app_type] => utility [patent_app_number] => 15/158638 [patent_app_country] => US [patent_app_date] => 2016-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 12 [patent_no_of_words] => 26780 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15158638 [rel_patent_id] =>[rel_patent_doc_number] =>)